Target Informatics Platform™ (TIP™)

Eidogen-Sertanty's Target Informatics Platform (TIP) is the world's first structural informatics system and knowledgebase that enables researchers with the ability to interrogate the druggable genome from a structural perspective. TIP amplifies the rapidly expanding body of experimental protein structure information and transforms structure-based drug discovery from a low-throughput, data scarce discipline into a high-throughput, data rich science. Designed to help bridge the knowledge gap between bioinformatics and cheminformatics, TIP supplies drug discovery researchers with a knowledgebase of information that is both distinct from and highly complementary to information furnished by existing bio- and cheminformatics platforms. TIP's seamless integration of structural data management technology with unique target-to-lead calculation and analysis capabilities enhances all stages of the discovery pipeline.

TIP's Value to Drug Discovery

  • Increase the Efficiency of Lead Discovery and Optimization
    • TIP enables chemists to derive an unprecedented level of relevant structural information that can be used to integrate rational and hypothesis-driven analyses into current and future lead discovery and optimization projects:
      • Quickly Identify Potential Leads using novel correlations between new annotated binding sites and sites with known ligands.
      • Improve Drug Selectivity with easy-to-use comparative binding site analysis and visualization tools.
      • Survey the Landscape of Target-Ligand Interactions across an entire family of drug targets, maximizing the knowledge that can be derived from structures with docked or co-crystallized ligands.

  • Discover New Opportunities for Validated Targets and Compounds
    • TIP furnishes reliable information about new opportunities and applications that can otherwise only be discovered via costly and time-consuming experimental efforts:
      • Discover and Evaluate Novel Binding Sites in previously validated and proven drug targets.
      • Develop Lead Hopping and Target Hopping strategies using pre-calculated similarities at the binding site, target-ligand interaction fingerprint, or ligand levels.

  • Increase the Overall Quality of the Target Portfolio
    • TIP supplies druggability and selectivity information to support highly informed target selection and prioritization decisions:
      • Quickly Understand Target Druggability based on a detailed annotation of available small molecule binding sites and understanding of gene family-wide similarity for targets of interest.
      • Derive Maximum Value from the Distribution of Target Knowledge utilizing TIP's centralized system for managing all structure, binding site annotation, selectivity, and co-crystallized and docked ligand interactions for all targets of interest, across all members of a project team.

TIP Drug Discovery Downloads

Exercising Receptor-Site Similarity Using Receptor-Site and Protein Structural Similarity to Generate New Matter Ideas Supporting your pipeline with structural knowledge

Example Drug Discovery Applications

  • Target Prioritization Applications
    • Target Druggability Assessment
      • Binding Site Property Analysis
      • Binding Site Selectivity Analysis
      • SNP structural mapping and analysis
      • Drug Resistance Mutation Analysis
      • Drug Target Clustering
    • Animal Model Suitability Analysis
    • Broad Spectrum Anti-Infective Target Analysis

  • Lead Discovery Applications
    • Novel Lead Fragment & Scaffold Discovery
    • Binding Site Property Analysis & HTS Library Selection
    • Structure-Based Library Design
    • VLS Binding Mode Analysis

  • Lead Optimization Applications
    • Structure-Based Ligand Affinity Optimization
    • Structure-Based Selectivity Optimization
    • Structure-Based Broad Spectrum Anti-Infective Optimization
    • Structure-Based Co-Inhibitor Affinity Optimization
    • "Off-Target" Discovery and Analysis
    • "Off-Target" Assay Panel Design

  • Opportunity Discovery
    • Novel Drug Rescue Opportunities
      • Due to Drug-Induced Mutations
      • Due to Poor Selectivity within a Family
      • Due to "Off-Target" Interactions
    • Novel Drug Redesign Opportunities
    • Novel Drug Binding Site Opportunities
    • Novel Co-Inhibition Opportunities
    • Novel Anti-infective opportunities